JP2022507830A5 - - Google Patents
Info
- Publication number
- JP2022507830A5 JP2022507830A5 JP2021527959A JP2021527959A JP2022507830A5 JP 2022507830 A5 JP2022507830 A5 JP 2022507830A5 JP 2021527959 A JP2021527959 A JP 2021527959A JP 2021527959 A JP2021527959 A JP 2021527959A JP 2022507830 A5 JP2022507830 A5 JP 2022507830A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- modified
- cells
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769987P | 2018-11-20 | 2018-11-20 | |
| US62/769,987 | 2018-11-20 | ||
| US201862774595P | 2018-12-03 | 2018-12-03 | |
| US62/774,595 | 2018-12-03 | ||
| US201962795810P | 2019-01-23 | 2019-01-23 | |
| US62/795,810 | 2019-01-23 | ||
| US201962828770P | 2019-04-03 | 2019-04-03 | |
| US62/828,770 | 2019-04-03 | ||
| US201962846563P | 2019-05-10 | 2019-05-10 | |
| US62/846,563 | 2019-05-10 | ||
| US201962848961P | 2019-05-16 | 2019-05-16 | |
| US62/848,961 | 2019-05-16 | ||
| US16/445,965 | 2019-06-19 | ||
| US16/445,965 US10918667B2 (en) | 2018-11-20 | 2019-06-19 | Modified cell expressing therapeutic agent and uses thereof |
| US201962889926P | 2019-08-21 | 2019-08-21 | |
| US62/889,926 | 2019-08-21 | ||
| US201962902766P | 2019-09-19 | 2019-09-19 | |
| US62/902,766 | 2019-09-19 | ||
| PCT/US2019/062417 WO2020106843A1 (en) | 2018-11-20 | 2019-11-20 | Modified cell expressing therapeutic agent and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022507830A JP2022507830A (ja) | 2022-01-18 |
| JP2022507830A5 true JP2022507830A5 (cg-RX-API-DMAC7.html) | 2022-11-29 |
Family
ID=70774027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021527959A Pending JP2022507830A (ja) | 2018-11-20 | 2019-11-20 | 治療薬を発現する改変細胞とその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20220000921A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3883585A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022507830A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019384145A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3120153A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202105173VA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020106843A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| BR112020025287A2 (pt) * | 2018-06-25 | 2021-03-09 | University Of Washington | Projeto de novo de miméticos de interleucina potentes e seletivos |
| US12410226B2 (en) | 2018-07-30 | 2025-09-09 | The Board Of Trustees Of The Leland Stanford Junior University | Interferon-gamma biased agonists |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| CN112638947B (zh) * | 2018-08-30 | 2022-09-30 | 上海斯丹赛生物技术有限公司 | 用于治疗实体瘤的嵌合抗原受体细胞 |
| US11866494B2 (en) * | 2018-08-31 | 2024-01-09 | Innovative Cellular Therapeutics Holdings, Ltd. | CAR T therapy through uses of co-stimulation |
| JP2022511390A (ja) | 2018-11-20 | 2022-01-31 | ユニバーシティ オブ ワシントン | 分割インターロイキン模倣体およびその使用 |
| JP2022531814A (ja) * | 2019-03-12 | 2022-07-12 | イノベイティブ セルラー セラピューティクス ホールディングス,エルティディ | 改変細胞の増幅およびその応用 |
| WO2021016194A1 (en) | 2019-07-19 | 2021-01-28 | Racaniello Vincent R | Second generation seneca valley virus oncolytic therapy: compositions and methods thereof |
| US12702708B2 (en) | 2019-08-21 | 2026-08-11 | Innovative Cellular Therapeutics Holdings, Ltd. | Presenting cell and use thereof in cell therapy |
| US20210060069A1 (en) * | 2019-08-23 | 2021-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Coupled redirected cells and uses thereof |
| BR112022009110A2 (pt) * | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| WO2021179967A1 (zh) * | 2020-03-09 | 2021-09-16 | 四川大学华西医院 | IFN-γ在制备抗肿瘤辅助药物中的应用 |
| EP3892720A1 (en) | 2020-04-06 | 2021-10-13 | Innovative Cellular Therapeutics Holdings, Ltd. | Presenting cell and use thereof in cell therapy |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| JP7633377B2 (ja) * | 2020-07-27 | 2025-02-19 | 中国科学院分子細胞科学卓越創新中心 | キメラ抗原受容体及びその用途 |
| US20230303975A1 (en) * | 2020-08-21 | 2023-09-28 | Julius-Maximilians-Universität Würzburg | Modified lymphocytes |
| WO2022079489A1 (en) * | 2020-10-12 | 2022-04-21 | Takeda Pharmaceutical Company Limited | Determination of cellular kinetics and biodistribution for car-t cells |
| WO2022159508A1 (en) * | 2021-01-19 | 2022-07-28 | Seneca Therapeutics, Inc. | Armed seneca valley virus oncolytic therapy compositions and methods thereof |
| US11633427B2 (en) * | 2021-02-05 | 2023-04-25 | Innovative Cellular Therapeutics Holdings, Ltd. | Vaccine and uses thereof in cell therapy |
| CN113046320B (zh) * | 2021-02-19 | 2023-04-14 | 中国医学科学院基础医学研究所 | 胞外段为Vδ1(GTM)Vγ4的CAR分子及表达该分子的CAR-T细胞及其用途 |
| WO2022216144A1 (en) * | 2021-04-08 | 2022-10-13 | GC Cell Corporation | Fusion proteins comprising chimeric antigen receptors and il-15 |
| CN114934071B (zh) * | 2021-04-30 | 2023-10-17 | 四川大学华西医院 | 一种表达免疫调节因子的car载体及其应用 |
| EP4215245A1 (en) | 2022-01-19 | 2023-07-26 | Innovative Cellular Therapeutics Holdings, Ltd. | Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment |
| EP4739334A1 (en) | 2023-07-05 | 2026-05-13 | Nanotein Technologies, Inc. | Cell signaling complexes and uses thereof |
| US12473529B2 (en) | 2023-07-18 | 2025-11-18 | Nanotein Technologies, Inc. | Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof |
| WO2025117789A1 (en) * | 2023-12-01 | 2025-06-05 | Parker Institute For Cancer Immunotherapy | Engineered immune signaling constructs |
| WO2025184172A1 (en) * | 2024-02-27 | 2025-09-04 | Overt Bio, Inc. | Cancer reactive t cell receptors |
| WO2025184170A1 (en) | 2024-02-27 | 2025-09-04 | Overt Bio, Inc. | Methods and compositions for improving t cell function in an immunosuppressive environment |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2292242T5 (es) * | 1998-05-15 | 2011-05-04 | Genentech, Inc. | Utilizaciones terapéuticas de polipéptidos homólogos de il-17. |
| JP2003513681A (ja) * | 1999-11-12 | 2003-04-15 | マキシゲン・ホールディングス・リミテッド | インターフェロンガンマ・コンジュゲート |
| AUPQ755300A0 (en) * | 2000-05-17 | 2000-06-08 | Monash University | Immune potentiating compositions |
| US7038015B2 (en) * | 2001-04-06 | 2006-05-02 | Maxygen Holdings, Ltd. | Interferon gamma polypeptide variants |
| US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| CA2508831C (en) * | 2002-12-13 | 2012-05-01 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| AU2010205782A1 (en) * | 2009-01-16 | 2011-09-08 | Agirx Limited | Vaccine compositions |
| WO2010126766A1 (en) * | 2009-04-30 | 2010-11-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible interleukin-12 |
| JP5975983B2 (ja) * | 2010-04-16 | 2016-08-23 | ベリカム ファーマシューティカルズ, インコーポレイテッド | 固形腫瘍を処置するための方法 |
| WO2012066495A2 (en) * | 2010-11-17 | 2012-05-24 | Ben Gurion University Of The Negev Research And Development Authority | T-cell therapy to neurodegenerative diseases |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP2014509841A (ja) * | 2011-01-18 | 2014-04-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するための組成物および方法 |
| AU2012267710A1 (en) * | 2011-06-08 | 2014-01-23 | The Regents Of The University Of California | Anti-CD22 antigen binding molecules to treat lung cancer and prostate cancer |
| JP6267644B2 (ja) * | 2011-10-20 | 2018-01-24 | アメリカ合衆国 | 抗cd22キメラ抗原受容体 |
| EP2997134B1 (en) * | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| WO2015092024A2 (en) * | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| WO2016113203A1 (en) * | 2015-01-12 | 2016-07-21 | Pieris Ag | Engineered t cells and uses therefor |
| US10493139B2 (en) * | 2015-07-24 | 2019-12-03 | Innovative Cellular Therapeutics CO., LTD. | Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor |
| SG10201913151TA (en) * | 2015-09-09 | 2020-03-30 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Genetic engineering of macrophages for immunotherapy |
| WO2017075537A1 (en) * | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| SG11201807489PA (en) * | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| CN113082201B (zh) * | 2016-04-01 | 2024-07-05 | 上海斯丹赛生物技术有限公司 | 刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法 |
| KR102614675B1 (ko) * | 2016-04-15 | 2023-12-19 | 메모리얼 슬로안 케터링 캔서 센터 | 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법 |
| CN118165113B (zh) * | 2016-04-26 | 2025-10-28 | 恺兴生命科技(上海)有限公司 | 一种改善免疫应答细胞功能的方法 |
| WO2018064921A1 (en) * | 2016-10-06 | 2018-04-12 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
| EP3571294A1 (en) * | 2017-01-18 | 2019-11-27 | F1 Oncology, Inc. | Methods of transducing and expanding immune cells and uses thereof |
| US10561686B2 (en) * | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
-
2019
- 2019-11-20 US US17/295,364 patent/US20220000921A1/en active Pending
- 2019-11-20 CA CA3120153A patent/CA3120153A1/en active Pending
- 2019-11-20 EP EP19887928.0A patent/EP3883585A4/en not_active Withdrawn
- 2019-11-20 WO PCT/US2019/062417 patent/WO2020106843A1/en not_active Ceased
- 2019-11-20 SG SG11202105173VA patent/SG11202105173VA/en unknown
- 2019-11-20 AU AU2019384145A patent/AU2019384145A1/en not_active Abandoned
- 2019-11-20 JP JP2021527959A patent/JP2022507830A/ja active Pending
-
2022
- 2022-05-20 US US17/749,824 patent/US20220339193A1/en active Pending